#1 Clinical Trials Search in Europe

Insulin Icodec

Insulin icodec is an innovative long-acting insulin analog currently being studied for the treatment of type 2 diabetes. This new medication is designed to be administered just once a week, potentially offering a more convenient option for patients compared to traditional daily insulin injections. Clinical trials are investigating how insulin icodec works in the body, its effectiveness in controlling blood sugar levels, and its safety profile in various patient populations.

Table of Contents

What is Insulin Icodec?

Insulin icodec is a new type of insulin that is currently being developed for the treatment of type 2 diabetes. Unlike traditional insulins that need to be injected daily, insulin icodec is designed to be administered just once a week[1]. This innovative approach could potentially make diabetes management more convenient for patients.

Insulin icodec is not yet available at pharmacies and is still undergoing clinical trials to evaluate its effectiveness and safety[2]. It’s being developed as an alternative to daily long-acting insulins like insulin degludec and insulin glargine, which are already on the market[1][3].

How Does Insulin Icodec Work?

Insulin icodec is a long-acting insulin analogue, which means it’s designed to provide a steady level of insulin in the body over an extended period. When injected under the skin, it slowly releases into the bloodstream over the course of a week, helping to control blood sugar levels throughout that time[4].

This new insulin aims to mimic the action of natural insulin produced by the body, which helps move glucose (sugar) from the blood into cells for energy. For people with type 2 diabetes who don’t produce enough insulin or whose bodies don’t use insulin effectively, insulin icodec can help maintain more stable blood sugar levels[1].

Benefits of Insulin Icodec

The main potential benefit of insulin icodec is its once-weekly dosing schedule. This could offer several advantages for patients:

  • Convenience: Instead of daily injections, patients would only need to inject insulin once a week. This could make diabetes management less burdensome and potentially improve treatment adherence[1].
  • Improved blood sugar control: Studies are investigating whether insulin icodec can provide better or similar blood sugar control compared to daily insulins[1][3].
  • Reduced injection burden: Fewer injections may lead to improved quality of life for patients with diabetes[5].

Administration and Dosage

Insulin icodec is administered as a subcutaneous injection, which means it’s injected into the fatty tissue just under the skin. The injection can be given in the thigh, upper arm, or stomach area[1].

The dosage of insulin icodec is individualized based on the patient’s needs. In clinical trials, researchers are studying various dosing regimens to determine the most effective and safe approach. Some studies are using a fixed dose based on body weight, while others are adjusting the dose based on the patient’s blood sugar levels[2][4].

To help patients monitor their blood sugar levels, some studies are using continuous glucose monitoring (CGM) systems or flash glucose monitors. These devices allow patients and healthcare providers to track blood sugar levels in real-time, which can help with insulin dose adjustments[5][1].

Ongoing Research

Several clinical trials are currently underway to evaluate various aspects of insulin icodec:

  • Efficacy and safety: Studies are comparing insulin icodec to existing daily insulins like insulin degludec and insulin glargine to see how well it controls blood sugar and assess its safety profile[1][3].
  • Pharmacokinetics: Researchers are studying how insulin icodec moves through the body, including how it’s absorbed, distributed, and eliminated[6][7].
  • Special populations: Some studies are looking at how insulin icodec works in specific groups, such as people with liver disease or children and adolescents with type 2 diabetes[8][2].
  • Exercise and fasting: Researchers are investigating how insulin icodec performs during exercise and prolonged fasting to ensure it’s safe and effective in various real-life situations[9].

Safety and Side Effects

As with all insulins, the main potential side effect of insulin icodec is hypoglycemia, or low blood sugar. This can occur if too much insulin is given relative to food intake or physical activity. Symptoms of hypoglycemia can include shakiness, sweating, confusion, and in severe cases, loss of consciousness[1].

Clinical trials are carefully monitoring for hypoglycemic events, including severe hypoglycemia, which requires assistance from another person to treat. Researchers are also tracking other potential side effects and comparing them to those of existing insulins[1][3].

It’s important to note that as insulin icodec is still in development, its full safety profile is not yet known. More information will become available as clinical trials progress.

Who Can Use Insulin Icodec?

Insulin icodec is being studied for use in adults with type 2 diabetes. Clinical trials are including both:

  • Insulin-naïve patients: People who have never used insulin before[3].
  • Insulin-experienced patients: People who are already using daily basal insulin[10].

However, there are some restrictions on who can participate in the current clinical trials. For example:

  • Pregnant or breastfeeding women are not eligible to participate[1].
  • People with certain serious health conditions may be excluded[8].
  • Some studies have specific age restrictions[8].

It’s important to remember that insulin icodec is not yet approved for general use. Once it completes all necessary clinical trials and if it receives regulatory approval, healthcare providers will determine which patients are suitable candidates for this new treatment based on individual factors and the medication’s approved indications.

Aspect Details
Drug Name Insulin Icodec
Administration Once-weekly subcutaneous injection
Target Population Adults with Type 2 Diabetes
Key Benefits Potential for improved treatment convenience and adherence
Main Outcome Measures Change in HbA1c, fasting plasma glucose, time in target blood glucose range
Safety Considerations Monitoring for hypoglycemia and other adverse events
Comparators in Trials Insulin degludec, insulin glargine
Special Populations Studied Patients with liver disease, children and adolescents with Type 2 Diabetes
Technology Used Continuous Glucose Monitoring (CGM) systems in some trials
Patient-Reported Outcomes Treatment satisfaction measured using questionnaires

FAQ

  • What is insulin icodec? Insulin icodec is a new long-acting insulin analog being developed for the treatment of type 2 diabetes. It is designed to be administered once a week, unlike traditional insulins that require daily injections.
  • How is insulin icodec administered? Insulin icodec is administered through a subcutaneous injection (under the skin) using a small needle. It can be injected into the thigh, upper arm, or stomach area.
  • What are the potential benefits of insulin icodec? The main potential benefit of insulin icodec is its once-weekly dosing schedule, which could improve treatment convenience and potentially enhance adherence for patients with type 2 diabetes compared to daily insulin injections.
  • How does insulin icodec compare to other long-acting insulins? Clinical trials are comparing insulin icodec to other long-acting insulins like insulin degludec. These studies are looking at factors such as blood sugar control, safety, and patient satisfaction to determine how insulin icodec performs compared to existing treatments.
  • What types of patients are being studied in insulin icodec clinical trials? Clinical trials are studying insulin icodec in various populations, including adults with type 2 diabetes who have not used insulin before, those already using basal insulin, and specific groups such as patients with liver disease, children and adolescents with type 2 diabetes.

Ongoing Clinical Trials on Insulin Icodec

  • Comparing weekly insulin icodec and daily insulin glargine with insulin aspart in adults with type 1 diabetes: a 26-week study of blood sugar control

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Poland Romania Slovakia

  • Comparison of weekly insulin icodec versus daily basal insulin in adults with type 2 diabetes who have not used insulin before

    Not yet recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Italy

  • A study comparing weekly insulin icodec and semaglutide with daily insulin degludec and insulin aspart in people with type 2 diabetes not well controlled on premixed insulin

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Poland

  • Study on the Effects of Switching from Daily Basal Insulin to Weekly Insulin Icodec Compared to Daily Insulin Glargine in Adults with Type 2 Diabetes

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Bulgaria Germany Poland Spain

  • Study on the Effectiveness of Weekly IcoSema (Insulin Icodec and Semaglutide) vs. Daily Insulin Glargine for Adults with Type 2 Diabetes Not Controlled by Oral Drugs

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Greece Italy Poland

  • Study on How Insulin Icodec and Semaglutide Help Control Blood Sugar in Patients with Type 2 Diabetes

    Not recruiting

    3 1 1
    Investigated drugs:
    Czechia Poland

Glossary

  • Insulin: A hormone that helps regulate blood sugar levels by allowing cells to use glucose from the bloodstream for energy.
  • Type 2 Diabetes: A chronic condition that affects the way your body processes glucose (sugar), often characterized by insulin resistance or insufficient insulin production.
  • Basal Insulin: Long-acting insulin that is typically taken once or twice daily to provide a steady level of insulin throughout the day and night.
  • Subcutaneous Injection: An injection given into the fatty tissue just beneath the skin.
  • HbA1c (Glycated Hemoglobin): A blood test that measures your average blood sugar levels over the past 2-3 months, used to diagnose and monitor diabetes.
  • Hypoglycemia: Low blood sugar, which can occur as a side effect of insulin treatment.
  • Continuous Glucose Monitoring (CGM): A method to track glucose levels throughout the day and night using a small sensor inserted under the skin.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Pharmacodynamics: The study of how a drug affects the body, including its mechanism of action and effectiveness.
  • Flash Glucose Monitor: A device that measures glucose levels continuously through a sensor worn on the body, allowing users to check their levels by scanning the sensor with a reader or smartphone.

References

  1. https://clinicaltrials.gov/study/NCT04770532
  2. https://clinicaltrials.gov/study/NCT05790681
  3. https://clinicaltrials.gov/study/NCT04460885
  4. https://clinicaltrials.gov/study/NCT04582435
  5. https://clinicaltrials.gov/study/NCT05823948
  6. https://clinicaltrials.gov/study/NCT04857398
  7. https://clinicaltrials.gov/study/NCT04582448
  8. https://clinicaltrials.gov/study/NCT04597697
  9. https://clinicaltrials.gov/study/NCT06288412
  10. https://clinicaltrials.gov/study/NCT06340854